Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses
暂无分享,去创建一个
T. Dwyer | A. Ponsonby | L. Blizzard | B. Taylor | H. Tremlett | I. van der Mei | Glenys A Paley | F. Pittas | I. A. van der Mei
[1] R. Snaith,et al. The hospital anxiety and depression scale. , 2013, Acta psychiatrica Scandinavica.
[2] M. Mura,et al. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis. , 2006, Functional neurology.
[3] Ross T Tsuyuki,et al. A meta-analysis of the association between adherence to drug therapy and mortality , 2006, BMJ : British Medical Journal.
[4] D. Paty,et al. Disability progression in multiple sclerosis is slower than previously reported , 2006, Neurology.
[5] L. Osterberg,et al. Adherence to medication. , 2005, The New England journal of medicine.
[6] X. Montalban,et al. Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis , 2005, Multiple sclerosis.
[7] A J Thompson,et al. Multiple sclerosis: diagnosis and the management of acute relapses , 2005, Postgraduate Medical Journal.
[8] M Hutchinson,et al. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns , 2005, Multiple sclerosis.
[9] B. Bergamasco,et al. High-dose, frequently administered interferon beta therapy for relapsing–remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study , 2004, Journal of the Neurological Sciences.
[10] V. Martinelli,et al. A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients , 2003, Journal of neurology, neurosurgery, and psychiatry.
[11] L. Munari,et al. Therapy with glatiramer acetate for multiple sclerosis. , 2003, The Cochrane database of systematic reviews.
[12] H. Tremlett,et al. Interrupted therapy , 2003, Neurology.
[13] R Brian Haynes,et al. Helping patients follow prescribed treatment: clinical applications. , 2002, JAMA.
[14] D. Goodin,et al. Randomized, comparative study of interferon β-1a treatment regimens in MS , 2002, Neurology.
[15] L. Kappos,et al. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS , 2002, Neurology.
[16] A. Ghezzi,et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) , 2002, The Lancet.
[17] T. T. Haug,et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. , 2002, Journal of psychosomatic research.
[18] L. Munari,et al. Interferon in relapsing-remitting multiple sclerosis. , 2001, The Cochrane database of systematic reviews.
[19] E. Vermeire,et al. Patient adherence to treatment: three decades of research. A comprehensive review , 2001, Journal of clinical pharmacy and therapeutics.
[20] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[21] B. Bergamasco,et al. Interferon-β dose and efficacy: the OPTIMS study , 2001, Neurological Sciences.
[22] D. Goodkin,et al. Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la , 1998, Multiple sclerosis.
[23] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[24] T. Perneger. What's wrong with Bonferroni adjustments , 1998, BMJ.
[25] D. Mohr,et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. , 1997, Archives of neurology.
[26] D. Mohr,et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment , 1996, Multiple sclerosis.
[27] R. Haynes,et al. Is this patient taking the treatment as prescribed , 1993 .
[28] K J Rothman,et al. No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.
[29] P. Albert,et al. Models for longitudinal data: a generalized estimating equation approach. , 1988, Biometrics.
[30] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[31] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[32] R B Haynes,et al. Predicting compliance with a regimen of digoxin therapy in family practice. , 1980, Canadian Medical Association journal.
[33] Hayden B. Bosworth,et al. Patient Treatment Adherence : Concepts, Interventions, and Measurement , 2008 .
[34] T. Tombaugh,et al. A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). , 2006, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.
[35] B. Bergamasco,et al. Interferon-beta dose and efficacy: the OPTIMS study. , 2001, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.
[36] Hristian,et al. RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS , 2000 .
[37] R. Haynes,et al. The rational clinical examination. Is this patient taking the treatment as prescribed? , 1993, JAMA.
[38] M. Graffar. [Modern epidemiology]. , 1971, Bruxelles medical.